6 results about "Multiple tumor" patented technology

The application discloses a classification method and device for pancreatic neuroendocrine tumors. The classification method comprises the following steps: segmenting tumor masks from enhanced CT images; for each tumor mask, generating a first peritumoral region and a second peritumoral region; dividing the tumor into multiple habitats for each tumor mask; extracting 3D radiomics features, multiple peritumoral microenvironment features, multiple tumor habitat features, multiple local pathological features and multiple global context features; selecting multiple target features for each enhanced CT image and calculating a radiomics score; inputting the radiomics score and clinical variables into a logistic regression model for training to obtain a trained logistic regression model; and using the trained logistic regression model to classify the enhanced CT images to be classified. The application can quickly and accurately realize G-grade classification of pancreatic neuroendocrine tumors, and provides a reliable non-invasive evaluation tool for clinical decision-making.

The invention relates to the technical field of image processing, in particular to an ultrasonic image ovarian tumor intelligent classification method, device and equipment and a medium. According to the method, the multiple tumor features are merged according to the similarity among the tumor features of the multiple ultrasonic images to obtain the redundancy-removed features, then the O-RADS score of the tumor is obtained based on the redundancy-removed features, and the O-RADS score comprises five scores, so that the lesion degree of the tumor can be more refined, and the evaluation result of the lesion degree of the tumor is improved. In addition, according to the method, the tumor features of each ultrasonic image are extracted separately, and then the final O-RADS score is obtained according to the tumor features of the multiple ultrasonic images. No matter how many ultrasonic images of a tumor are collected, the feature of each ultrasonic image can be independently extracted, and no matter how many tumor features are, an O-RADS score can be obtained, so that the collected ultrasonic images are not limited by evaluating the lesion degree of the tumor based on the O-RADS score, and the accuracy of evaluating the lesion degree of the tumor based on the O-RADS score is improved. Therefore, more ultrasonic images are allowed to be used for evaluating the tumor lesion degree, and the tumor lesion degree evaluation precision is further improved.

This invention provides a continuous implantation device for PDX model tumor tissue, comprising: a main cannula; and a pushing component disposed at one end of the main cannula. The continuous implantation device for PDX model tumor tissue provided by this invention utilizes the cooperation of structures such as the main cannula, the pushing component, the tissue sampler, and the retaining spring. The tissue sampler can be pre-loaded with multiple tumor tissue blocks, the retaining spring enables precise positioning and switching of the tissue sampler, the pushing component can sequentially push the tissue blocks for implantation, and the main cannula can be externally connected to an syringe to achieve simultaneous delivery of gel and tissue blocks. This device enables continuous implantation of tumor tissue blocks without the need for repeated clamping and transfer operations, significantly improving implantation efficiency and avoiding the decrease in activity caused by prolonged exposure of tissue blocks outside the body. Furthermore, it eliminates the need for clamping tissue blocks during transfer, reducing the risk of mechanical damage and ensuring the integrity of the tissue blocks. It also enables simultaneous delivery of tissue blocks, gel, and drugs, improving the experimental adaptability of the device.

The invention relates to a bionic intelligent microneedle tumor vaccine as well as a preparation method and application thereof. According to the vaccine, coaxial electrostatic spraying is utilized to construct a drug-loaded microsphere with a core-shell structure, the drug-loaded microsphere is coated with cancer cell-derived membrane protein, and then the drug-loaded microsphere is fixed at the needle point part of a soluble microneedle in a centrifugal manner, so that local drug delivery of crossing a cuticle layer and accurately delivering the drug-loaded microsphere to a corium layer is realized. The microsphere can load demethylated drugs DAC and TAM at the same time, and realizes responsive controlled release in a tumor microenvironment. A plurality of tumor-associated antigens and apoptosis-associated injury-associated molecular patterns carried by the cancer cell membrane protein can promote the maturation of dendritic cells and activate the specific T cell mediated anti-tumor immune response. In conclusion, the microneedle vaccine system integrates multiple functions of precise delivery, controllable release, chemical kinetics treatment, epigenetic regulation, immune activation and the like, the anti-tumor immunotherapy effect can be effectively enhanced, and a new strategy is provided for tumor immunotherapy.

The application provides an antitumor delphinine alkaloid in Caesalpinia minax, a core skeleton of angustifoline type, and provides an extraction method and application, and compound 3 is used for preparation of an antitumor drug. The natural delphinine with a new angustifoline type structural skeleton is obtained by separation and extraction, wherein compound 3 has a significant inhibitory effect on multiple tumor cell strains, and can be used for preparation of an antitumor drug.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.